Neuberger Berman Group LLC Buys 9,791 Shares of QIAGEN N.V. $QGEN

Key Points

• Neuberger Berman Group LLC increased its holdings in Qiagen N.V. by 102.4% in Q1, acquiring an additional 9,791 shares and bringing its total to 19,352 shares valued at approximately $767,000.
• Qiagen reported Q2 earnings of $0.60 EPS, meeting analyst expectations, with a revenue of $533.54 million, up 7.7% year-over-year.
• The company announced a $0.25 per share dividend with a yield of 52.0%, reflecting a dividend payout ratio of 14.79%.

Neuberger Berman Group LLC lifted its position in QIAGEN N.V. (NYSE:QGEN - Free Report) by 102.4% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 19,352 shares of the company's stock after purchasing an additional 9,791 shares during the quarter. Neuberger Berman Group LLC's holdings in QIAGEN were worth $767,000 at the end of the most recent reporting period.

Several other institutional investors have also bought and sold shares of the stock. Exchange Traded Concepts LLC boosted its stake in QIAGEN by 2.3% in the first quarter. Exchange Traded Concepts LLC now owns 17,825 shares of the company's stock worth $716,000 after purchasing an additional 395 shares in the last quarter. LPL Financial LLC increased its holdings in QIAGEN by 2.6% in the fourth quarter. LPL Financial LLC now owns 17,240 shares of the company's stock valued at $768,000 after purchasing an additional 432 shares during the last quarter. Commerce Bank grew its stake in QIAGEN by 20.4% in the fourth quarter. Commerce Bank now owns 5,931 shares of the company's stock valued at $264,000 after acquiring an additional 1,004 shares during the period. Cetera Investment Advisers grew its stake in QIAGEN by 14.4% in the fourth quarter. Cetera Investment Advisers now owns 11,297 shares of the company's stock valued at $505,000 after acquiring an additional 1,418 shares during the period. Finally, GAMMA Investing LLC grew its stake in QIAGEN by 93.9% in the first quarter. GAMMA Investing LLC now owns 2,943 shares of the company's stock valued at $118,000 after acquiring an additional 1,425 shares during the period. Institutional investors and hedge funds own 70.00% of the company's stock.

QIAGEN Stock Performance

NYSE:QGEN traded down $0.03 on Wednesday, hitting $49.16. The company's stock had a trading volume of 499,550 shares, compared to its average volume of 1,373,756. The company has a current ratio of 1.61, a quick ratio of 1.35 and a debt-to-equity ratio of 0.25. The stock has a fifty day moving average of $48.48 and a two-hundred day moving average of $43.77. The firm has a market capitalization of $10.93 billion, a P/E ratio of 28.99, a price-to-earnings-growth ratio of 2.55 and a beta of 0.64. QIAGEN N.V. has a one year low of $37.63 and a one year high of $51.88.

QIAGEN (NYSE:QGEN - Get Free Report) last released its quarterly earnings results on Tuesday, August 5th. The company reported $0.60 earnings per share for the quarter, hitting the consensus estimate of $0.60. The business had revenue of $533.54 million during the quarter, compared to analysts' expectations of $523.97 million. QIAGEN had a return on equity of 14.77% and a net margin of 18.30%.The firm's revenue for the quarter was up 7.7% compared to the same quarter last year. During the same period last year, the firm posted $0.55 EPS. QIAGEN has set its Q3 2025 guidance at 0.580- EPS. FY 2025 guidance at 2.350-2.350 EPS. Research analysts predict that QIAGEN N.V. will post 2.26 earnings per share for the current year.

QIAGEN Dividend Announcement

The firm also recently disclosed a dividend, which was paid on Thursday, July 10th. Shareholders of record on Thursday, July 3rd were issued a $0.25 dividend. The ex-dividend date of this dividend was Wednesday, July 2nd. This represents a yield of 52.0%. QIAGEN's payout ratio is currently 14.79%.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on QGEN shares. Cowen reissued a "hold" rating on shares of QIAGEN in a research note on Thursday, August 7th. UBS Group upped their price objective on QIAGEN from $48.00 to $50.00 and gave the stock a "neutral" rating in a research report on Thursday, August 7th. Wall Street Zen cut QIAGEN from a "strong-buy" rating to a "buy" rating in a research report on Monday, August 11th. Bank of America upped their price objective on QIAGEN from $50.00 to $53.00 and gave the stock a "buy" rating in a research report on Thursday, June 26th. Finally, Barclays assumed coverage on QIAGEN in a research report on Tuesday, June 24th. They set an "overweight" rating and a $55.00 price objective for the company. Three investment analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Hold" and an average price target of $49.69.

QIAGEN Company Profile

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.